Dr. Nosha Farhadfar serves as Director of Research and Innovation at the Sarah Cannon Adult Stem Cell and Cellular Therapy Program. Her work integrates scientific discovery with compassionate care, guiding the Allianceโs global initiatives in education, innovation, and international research collaboration.
Dr. Nosha Farhadfar is a full-time faculty member at the Sarah Cannon Transplant and Cellular Therapy Program at Methodist Hospital, where she also serves as the Director of Research. She is a board-certified hematologist and medical oncologist with specialized expertise in hematopoietic cell transplantation and hematologic malignancies. Her academic and clinical career reflects a deep commitment to improving long-term outcomes and quality of life for transplant survivors.
Dr. Farhadfar completed fellowship training in blood and marrow transplantation at both the Mayo Clinic and the Fred Hutchinson Cancer Center, where her work focused on long-term follow-up and chronic graft-versus-host disease (GVHD). Motivated by a career goal to become a leading clinical investigator in transplant survivorship and complications, she joined the University of Florida in 2016 in a research-oriented role, where she founded and directed the Blood and Marrow Transplant Survivorship and GVHD Clinic, a position she held until transitioning to the Sarah Cannon network in 2023.
Her research portfolio centers on understanding and mitigating complications in transplant survivors, with a particular emphasis on interventions that enhance post-transplant quality of life. Dr. Farhadfar has led multiple clinical trials exploring the relationship between dietary intake, microbiota, and GVHD. In recognition of her expertise, she was selected as a member of the 2020 NIH Chronic GVHD Working Group and contributed to the development of standardized definitions and procedures for clinical trials, authoring the section on cutaneous GVHD in the groupโs white paper.
Dr. Farhadfar has dedicated the past decade to advancing clinical research in hematologic malignancies and stem cell transplantation. She has served as the site Principal Investigator for over twenty clinical trials, demonstrating consistent leadership and commitment to improving patient outcomes through evidence-based medicine. Her leadership extends to national and international research collaborations, including her role on the protocol team for the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) trial 1702, which investigates long-term outcomes of alternative donor allogeneic transplantation. She has also led international teams in six NIH-supported studies through the Center for International Blood and Marrow Transplant Research (CIBMTR). Dr. Farhadfar has authored more than 100 peer-reviewed publications, reflecting her sustained commitment to advancing the science and care of transplant recipients.
Her clinical work integrates evidence-based medicine, multidisciplinary collaboration, and a focus on improving the quality of life and long-term outcomes of transplant recipients.
Dr. Zoghiโs academic and research work spans translational science, immunotherapy, and stem-cell biology. He has contributed to national and international clinical trials in areas such as:
His publications and clinical trials have helped shape modern standards in transplant care and immune reconstitution.
Certifications: American Board of Internal Medicine including:
Dr. Farhadfar is deeply committed to mentoring young Persian physicians and advancing innovation in cellular therapy to improve the lives of patients worldwide.
โMy passion lies in improving survivorship for transplant patients โ not only helping them live longer, but live better. Every patientโs story continues long after transplant, and it is our responsibility to guide them through that journey.โ
